Original article title
FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
Source excerpt
“Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.”
Keep in mind
FDA announcement · read the approved indication and limitations.
www.fda.gov
The excerpt is quoted from source text. The original title is preserved above.
This is a reading aid. Follow the source for methods, limitations, corrections, and clinical context.